Kineret

Anakinra, the active ingredient in Kineret, is an interleukin‑1 receptor antagonist presented as a 100 mg/0.67 mL injectable solution for subcutaneous use. It treats rheumatoid arthritis and several autoinflammatory conditions in adults and children, including CAPS, NOMID, systemic juvenile idiopathic arthritis and gout flares.

GNH USA supplies Kineret as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kineret is an interleukin‑1 pathway inhibitor used in several inflammatory and autoinflammatory diseases. - Rheumatoid arthritis: reduces signs and symptoms of disease activity in adult patients. - Cryopyrin‑Associated Periodic Syndromes (CAPS): controls recurrent fever and systemic inflammation. - Neonatal‑onset multisystem inflammatory disease (NOMID): mitigates chronic inflammatory manifestations. - Systemic juvenile idiopathic arthritis (SJIA): improves joint symptoms and systemic features. - Gout flares: provides rapid relief of acute inflammatory attacks.

Adverse reactions may occur with Kineret therapy.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort. - Upper respiratory tract infection: symptoms of cold or sinusitis. - Arthralgia: transient joint pain. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Neutropenia: significant reduction in neutrophil count. - Serious infections: bacterial, fungal, or viral infections requiring medical attention. - Hypersensitivity reactions: anaphylaxis, angioedema, or severe skin reactions. - Hepatitis: elevated liver enzymes or clinical hepatitis. - Malignancy: rare reports of cancer development. - Injection‑site abscess: localized infection requiring drainage.

Before initiating Kineret, clinicians should consider several safety measures. - Monitor infection risk: assess for active infections and advise patients to report new signs promptly. - Screen for neutropenia: obtain baseline and periodic complete blood counts. - Assess hypersensitivity: discontinue if severe allergic reactions occur. - Use caution in pregnancy: category B, weigh benefits against potential risks. - Adjust in renal impairment: dose may need modification in severe renal dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kineret may interact with other agents that affect immune function.

Major Interactions (Avoid): - Live attenuated vaccines: concurrent use can increase risk of vaccine‑derived infection. - Other IL‑1 antagonists: co‑administration may lead to excessive immunosuppression.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined use may heighten infection susceptibility. - Methotrexate: may require enhanced hepatic monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor renal function and gastrointestinal tolerance. - Antimicrobial prophylaxis: adjust based on infection risk assessment. - Immunosuppressive biologics: observe for additive immunosuppressive effects.